Get the Stockscreener App
8.69
3.33%
0.29
Gyre Therapeutics Inc stock is traded at $8.69, with a volume of 102.78K.
It is up +3.33% in the last 24 hours and down -10.61% over the past month.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
See More
Previous Close:
$8.40
Open:
$8.44
24h Volume:
102.78K
Relative Volume:
0.76
Market Cap:
$786.34M
Revenue:
$106.66M
Net Income/Loss:
$15.16M
P/E Ratio:
92.94
EPS:
0.0935
Net Cash Flow:
$6.37M
1W Performance:
+3.33%
1M Performance:
-10.61%
6M Performance:
-37.96%
1Y Performance:
-45.61%
1-Day Range:
$8.26
$8.8898
1-Week Range:
$7.85
$9.385
52-Week Range:
$6.11
$19.00
Gyre Therapeutics Inc Stock (GYRE) Company Profile
Name
Gyre Therapeutics Inc
Sector
Industry
Phone
(619) 949-3681
Address
12770 HIGH BLUFF DRIVE, SUITE 150, SAN DIEGO
Compare GYRE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GYRE
Gyre Therapeutics Inc
|
8.64 | 786.34M | 106.66M | 15.16M | 6.37M | 0.0935 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.69 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
583.23 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
600.69 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.00 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.05 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-11-25 | Initiated | Noble Capital Markets | Outperform |
| Apr-29-21 | Resumed | Stephens | Overweight |
| Feb-10-21 | Initiated | Piper Sandler | Overweight |
| May-21-20 | Initiated | Raymond James | Outperform |
| Jan-04-19 | Initiated | Oppenheimer | Outperform |
| Feb-12-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Feb-09-18 | Reiterated | Chardan Capital Markets | Buy |
| Dec-08-17 | Initiated | B. Riley FBR, Inc. | Buy |
| Jun-12-17 | Initiated | Chardan Capital Markets | Buy |
| Jun-06-17 | Initiated | Ladenburg Thalmann | Buy |
| Jun-30-16 | Initiated | Rodman & Renshaw | Buy |
View All
Gyre Therapeutics Inc Stock (GYRE) Latest News
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
GYRE Stock Plummets to 52-Week Low at $6.15 Amid Market Challenges - Investing.com Canada
GYRE Stock Hits 52-Week Low at $8.26 Amid Market Challenges - Investing.com UK
Gyre Therapeutics Says China's NMPA Approves Pirfenidone Trial in Lung Injury - MarketScreener
Gyre Therapeutics announces NMPA approval for trial on pirfenidone - TipRanks
Major Breakthrough: Gyre's Cancer Drug Trial Targets 25% of Radiation Therapy Patients - Stock Titan
Bank of New York Mellon Corp Has $168,000 Stock Holdings in Gyre Therapeutics, Inc. (NASDAQ:GYRE) - Defense World
Gyre Therapeutics announces publication of protocol for Phase 3 trial on F351 - TipRanks
We Think You Should Be Aware Of Some Concerning Factors In Gyre Therapeutics' (NASDAQ:GYRE) Earnings - Yahoo Finance
Major Breakthrough: New Phase 3 Trial Targets Chronic Hepatitis B Liver Fibrosis Treatment - Stock Titan
Gyre therapeutics president Ma Songjiang sells common stock for $1,740 By Investing.com - Investing.com Canada
Gyre therapeutics president Ma Songjiang sells common stock for $1,740 - Investing.com Australia
Gyre Therapeutics (NASDAQ:GYRE) Trading Down 4.7% – Here’s Why - Defense World
Gyre therapeutics president Ma Songjiang sells $40,440 in stock By Investing.com - Investing.com Canada
Gyre therapeutics president Ma Songjiang sells $40,440 in stock - Investing.com India
GyreIntriguing Upcoming Data Catalyst, But I'm Still On Sidelines (NASDAQ:GYRE) - Seeking Alpha
Gyre Therapeutics Reports Strong Turnaround in 2024 Earnings - TipRanks
Gyre Therapeutics president Ma Songjiang sells $26,658 in stock By Investing.com - Investing.com India
Gyre Therapeutics president Ma Songjiang sells $26,658 in stock - Investing.com
Gyre Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Gyre Therapeutics Inc (GYRE) Q4 2024 Earnings: Revenue Surpasses Estimates at $27.9M, EPS Misses at $0.00 - GuruFocus.com
Impact of New U.S. Regulations on Gyre Therapeutics: Potential Delisting Risks and Investor Concerns - TipRanks
Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Down on Disappointing Earnings - Defense World
S&P 500 Down 1%; Sarepta Therapeutics Shares Plunge - Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Gyre Therapeutics (GYRE) Projected to Post Earnings on Tuesday - Defense World
Decoding Gyre Therapeutics Inc (GYRE): A Strategic SWOT Insight - GuruFocus
Gyre Therapeutics offers weak 2025 revenue guidance - Investing.com India
Gyre Therapeutics offers weak 2025 revenue guidance By Investing.com - Investing.com Canada
Gyre Therapeutics Reports Breakeven in Q4 as Revenue Increases -March 17, 2025 at 04:52 pm EDT - Marketscreener.com
Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - The Manila Times
(GYRE) Gyre Therapeutics Sees 2025 Revenue Range $118M$128M -March 17, 2025 at 04:18 pm EDT - Marketscreener.com
FY2024 Earnings Forecast for GYRE Issued By Noble Financial - Defense World
Gyre Therapeutics president Ma Songjiang sells $46,280 in stock By Investing.com - Investing.com Canada
Gyre Therapeutics president Ma Songjiang sells $46,280 in stock - Investing.com India
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Exploring High Growth Tech Stocks In The US March 2025 - Simply Wall St
Gyre therapeutics president Ma Songjiang sells $40,776 in stock By Investing.com - Investing.com South Africa
Gyre Therapeutics (NASDAQ:GYRE) Coverage Initiated by Analysts at Noble Financial - Defense World
Gyre therapeutics president Ma Songjiang sells $40,776 in stock - Investing.com
Noble Capital Initiates Coverage on Gyre Therapeutics With Outperform Rating, $20 Price Target - Marketscreener.com
Gyre Therapeutics initiated with an Outperform at Noble Capital - TipRanks
Gyre Therapeutics president Ma Songjiang sells $42,480 in stock - MSN
Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Up – Still a Buy? - Defense World
Gyre Therapeutics president Ma Songjiang sells $43,560 in stock - Investing.com India
Gyre Therapeutics president Ma Songjiang sells $43,560 in stock By Investing.com - Investing.com South Africa
Gyre Therapeutics Inc Stock (GYRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Gyre Therapeutics Inc Stock (GYRE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ma Songjiang | President |
Mar 21 '25 |
Sale |
10.00 |
174 |
1,740 |
2,824,844 |
| Ma Songjiang | President |
Mar 19 '25 |
Sale |
10.13 |
2,000 |
20,260 |
2,827,018 |
| Ma Songjiang | President |
Mar 20 '25 |
Sale |
10.09 |
2,000 |
20,180 |
2,825,018 |
| Ma Songjiang | President |
Mar 17 '25 |
Sale |
12.09 |
2,000 |
24,180 |
2,829,260 |
| Ma Songjiang | President |
Mar 18 '25 |
Sale |
10.24 |
242 |
2,478 |
2,829,018 |
| Ma Songjiang | President |
Mar 14 '25 |
Sale |
12.31 |
2,000 |
24,620 |
2,831,260 |
| Ma Songjiang | President |
Mar 13 '25 |
Sale |
11.80 |
2,000 |
23,600 |
2,833,260 |
| Ma Songjiang | President |
Mar 12 '25 |
Sale |
11.74 |
2,000 |
23,480 |
2,835,260 |
| Ma Songjiang | President |
Mar 11 '25 |
Sale |
11.40 |
2,000 |
22,800 |
2,837,260 |
| Ma Songjiang | President |
Mar 07 '25 |
Sale |
10.25 |
2,000 |
20,496 |
2,841,260 |
1.75%
2.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):